logo

DSGN

Design Therapeutics·NASDAQ
--
--(--)
--
--(--)
2.16 / 10
Underperform

DSGN's fundamental assessment is weak, with a composite score of 2.16/10. Key concerns include a low Net profit / Total profit ratio of 100% (score 0) and negative Revenue-MV and Asset-MV values, placing them in less favorable performance groups. Conversely, strong Inventory turnover (47.85, group 2) and Cash-MV (score 2) offer some relief. The PB-ROE factor of 0.9696 sits in group 2, providing a modest quality score. Overall, the fundamentals argue for caution.

Fundamental(2.16)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.26
Score1/3
Weight12.12%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight10.65%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.94%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight18.14%
1M Return7.79%
PB-ROE
Value0.97
Score1/3
Weight16.75%
1M Return7.02%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.12%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.55%
1M Return0.86%
Asset-MV
Value-0.50
Score1/3
Weight21.99%
1M Return8.74%
Cash-MV
Value-0.07
Score2/3
Weight18.16%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.54%
1M Return-0.30%
Is DSGN fundamentally strong?
  • DSGN scores 2.16/10 on fundamentals and holds a Premium valuation at present. Backed by its -24.35% ROE, 0.00% net margin, -9.21 P/E ratio, 2.93 P/B ratio, and -40.00% earnings growth, these metrics solidify its Underperform investment rating.